Scribd Logo
Upload

Welcome to Scribd!

  • PL 070511

    Uploaded by

    api-57047507
    14 views1 page
    Neolac Inc.'s five year business plan projects increasing revenues and profits over five years from its four sterilized nutritional product lines: Sterilac, Sterimilk, Sterilipid, and Steritrophic. In year 1, Neolac projects a net loss of $5.1 million but forecasts growing profits each subsequent year, with a net profit of $443 million projected for year 5, representing a net margin of 23.8%. Research and development, sales and marketing, and general administrative expenses are projected to increase each year to support revenue growth.

    Original Description:

    Original Title

    pl 070511

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    Neolac Inc.'s five year business plan projects increasing revenues and profits over five years from its four sterilized nutritional product lines: Sterilac, Sterimilk, Sterilipid, and Steritrophic. In year 1, Neolac projects a net loss of $5.1 million but forecasts growing profits each subsequent year, with a net profit of $443 million projected for year 5, representing a net margin of 23.8%. Research and development, sales and marketing, and general administrative expenses are projected to increase each year to support revenue growth.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as pdf or txt
    14 views1 page

    PL 070511

    Uploaded by

    api-57047507
    Neolac Inc.'s five year business plan projects increasing revenues and profits over five years from its four sterilized nutritional product lines: Sterilac, Sterimilk, Sterilipid, and Steritrophic. In year 1, Neolac projects a net loss of $5.1 million but forecasts growing profits each subsequent year, with a net profit of $443 million projected for year 5, representing a net margin of 23.8%. Research and development, sales and marketing, and general administrative expenses are projected to increase each year to support revenue growth.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as pdf or txt
    of 1

    Neolac, Inc.

    Five Year Business Plan


    Profit & Loss Statement
    ($000's)
    Description
    Net Revenues
    Sterilac
    Sterimilk
    Sterilipid
    Steritrophic
    Total Net Revenues

    Year 1

    Year 2

    Year 3

    Year 4

    Year 5

    $4,374.0
    4,665.0

    $117,307.0
    125,093.0

    $256,356.0
    273,412.0

    $500,910.0
    534,249.0

    $898,983.0
    958,806.0

    31.0
    9,070.0

    836.0
    243,236.0

    1,825.0
    531,593.0

    3,557.0
    1,038,716.0

    6,407.0
    1,864,196.0

    Total Cost of Sales

    4,579.1

    74,155.5

    177,199.6

    346,664.1

    626,026.5

    Gross Profit
    Gross Margin

    4,490.9
    49.5%

    169,080.5
    69.5%

    354,393.4
    66.7%

    692,051.9
    66.6%

    1,238,169.5
    66.4%

    Overhead Expenses
    Research & Development
    Sales & Marketing
    General & Administrative
    Total Overhead Expenses

    4,171.0
    2,112.0
    3,362.3
    9,645.3

    8,872.4
    34,662.5
    14,346.5
    57,881.4

    34,548.0
    75,537.3
    28,385.0
    138,470.3

    65,229.6
    144,410.1
    49,988.6
    259,628.3

    117,895.4
    249,446.8
    81,626.3
    448,968.5

    (5,154.4)
    -56.8%

    111,199.1
    45.7%

    215,923.1
    40.6%

    432,423.6
    41.6%

    789,201.0
    42.3%

    (5,154.4)

    111,199.1

    215,923.1

    432,423.6

    789,201.0

    (46,490.0)

    (94,661.0)

    (189,574.0)

    (345,986.0)

    $242,849.6

    $443,215.0

    Operating Income
    Operating Margin
    Total Other Income/(Expense)
    Profit/(Loss) Before Tax
    Provision For Taxes
    Net Profit/(Loss)
    Net Margin

    ($5,154.4)
    -56.8%

    $64,709.1
    26.6%

    $121,262.1
    22.8%

    23.4%

    23.8%

    You might also like